2. Signaling Pathways
  3. Others
  4. Drug Derivative

Drug Derivative

Drug derivative

 

Drug Derivative Related Products (1110):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-I0960
    Uracil
    		99.97%
    Uracil is a pyrimidine derivative and one of the four nucleobases in the nucleic acid of RNA. Uracil is a frequently occurring DNA base damage that results from the spontaneous or chemically induced deamination of cytosine and is mutagenic at the level of replication. Uracil could potentially alter transcriptional fidelity, resulting in production of mutant proteins.
    Uracil
  • HY-A0132
    N-Acetyl-D-glucosamine
    		99.20%
    N-Acetyl-D-Glucosamine (N-Acetyl-2-amino-2-deoxy-D-glucose), the D isomer of N-acetylglucosamine, is an orally active monosaccharide derivative of glucose with anti-tumor and anti-inflammation properties. N-Acetyl-D-Glucosamine is also a bacterial metabolite, which is found in Escherichia coli. N-Acetyl-D-Glucosamine can induce yeast-mycelial conversion in Candida albicans. N-Acetyl-D-Glucosamine also enhances healing of cartilaginous injuries in rabbits.
    N-Acetyl-D-glucosamine
  • HY-106406
    Benzylacyclouridine
    		98.18%
    Benzylacyclouridine (BAU) is a potent and specific inhibitor of uridine phosphorylase, the first enzyme in the catabolism of uridine. Benzylacyclouridine can modulate the cytotoxic side effects of 5-fluorouracil (5-FU) and its derivatives.
    Benzylacyclouridine
  • HY-131296
    5-A-RU-PABC-Val-Cit-Fmoc
    		98.85%
    5-A-RU-PABC-Val-Cit-Fmoc is the proagent of 5-A-RU. 5-A-RU, a precursor of bacterial Riboflavin, is a mucosal-associated invariant T (MAIT) cells activator. 5-A-RU forms potent MAIT-activating antigens via non-enzymatic reactions with small molecules, such as glyoxal and methylglyoxal, which are derived from other metabolic pathways.
    5-A-RU-PABC-Val-Cit-Fmoc
  • HY-160214
    Perforin-IN-2
    		99.43%
    Perforin-IN-2 is a benzosulfonamide perforin inhibitor that alleviates transplant rejection during allogeneic bone marrow/stem cell transplantation. Perforin-IN-2 binds to plasma proteins with a binding rate of 99.8%. Perforin-IN-2 requires a higher concentration (> 900 μM) to achieve optimal perforin inhibition in vivo. Perforin-in-2 can effectively inhibit the lytic activity of recombinant perforin on Jurkat T (IC50=6.65 μM) leukemia cells, and also inhibit the death of K562 leukemia target cells.
    Perforin-IN-2
  • HY-79139
    Pteroic acid
    		98.03%
    Pteroic acid is an active compound.
    Pteroic acid
  • HY-I0450
    Anticancer agent 265
    		99.74%
    Anticancer agent 265 (compound 1) is an anticancer compound. Anticancer agent 265 exhibits in vitro anticancer activity against three human bone cancer lines, U2OS, Saos-2, and GC9811, with IC50 values ​​of 13.1, 11.7, and 14.6 μM, respectively.
    Anticancer agent 265
  • HY-W017764
    7,8-Dihydro-2,5(1H,6H)-quinolinedione
    7,8-Dihydro-2,5(1H,6H)-quinolinedione (compound SF32) is a positive inotropic agent.
    7,8-Dihydro-2,5(1H,6H)-quinolinedione
  • HY-B0079
    Sugammadex sodium
    		≥98.0%
    Sugammadex sodium is a synthetic γ-cyclodextrin derivative, and acts as a reversal agent for neuromuscular block. Sugammadex sodium shows nephroprotective effect in ischemia-reperfusion injury.
    Sugammadex sodium
  • HY-W011053
    Neotame
    		98.00%
    Neotame is a derivative of Aspartame (HY-B0361) and is a flavor enhancer and low-caloric, non-nutritive, high-intensity artificial sweetener that is 7000-13,000 times sweeter than sugar. Neotame causes intestinal epithelial cell death at high concentrations. Neotame induces Apoptosis of Caco-2 cells.
    Neotame
  • HY-131394
    5-Hydroxymethyl-2’-deoxycytidine
    		99.96%
    5-Hydroxymethyl-2’-deoxycytidine (5hmdC) is an oxidation derivative of 5-methyl-2'-deoxycytidine (5-mdC) in DNA. 5-Hydroxymethyl-2’-deoxycytidine may serve as a marker of irreversibly damaged cells.
    5-Hydroxymethyl-2’-deoxycytidine
  • HY-122682
    SBI-993
    		98.67%
    SBI-993 is a SBI-477 analog with improved potency and suitable pharmacokinetic properties for in vivo bioavailability. SBI-993 stimulates insulin signaling by deactivating the transcription factor MondoA.
    SBI-993
  • HY-B2102
    Oxyphenisatine
    		98.42%
    Oxyphenisatine (Oxyphenisatin) is a laxative. Oxyphenisatin acetate is the pro-agent of oxyphenisatin with anticancer activity.
    Oxyphenisatine
  • HY-139409A
    2-Deoxy-D-glucose 6-phosphate disodium
    		≥98.0%
    2-Deoxy-D-glucose 6-phosphate disodium, a derivative of 2-Deoxy-D-glucose, is produced in mammalian cells by the action of hexokinase on 2-DG. 2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexokinase.
    2-Deoxy-D-glucose 6-phosphate disodium
  • HY-W005627
    Linoleyl alcohol
    		99.84%
    Linoleyl alcohol, a structural analog of Linoleic acid with no a-carboxyl group, is a fatty alcohol.
    Linoleyl alcohol
  • HY-136506
    NUC-7738
    NUC-7738, an aryloxy phosphoramidate of 3′-Deoxyadenosine, is a 5′-aryloxy phosphoramidate prodrug of 3′-Deoxyadenosine (3′-dA). NUC-7738 has potent cytotoxic activity against a panel of hematological cancer cell lines. NUC-7738 can be used in research of cancer.
    NUC-7738
  • HY-160429
    PSAR18-COOH
    		99.86%
    PSAR18-COOH is a derivative of PSAR extracted from patent WO2009064913A1. PSAR is a highly hydrophilic, biodegradable, non-immunogenic and water-soluble polymer that has been employed in several delivery systems for drugs or diagnostics.
    PSAR18-COOH
  • HY-111179
    ML261
    		99.80%
    ML261 is a hepatic lipid droplets formation inhibitor with an IC50 value of 69.7 nM. ML261 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and inflammation.
    ML261
  • HY-100438
    Hydronidone
    		99.92%
    Hydronidone is a pyridine derivative and an antifibrotic agent for hepatic fibrosis.
    Hydronidone
  • HY-12424
    Zotarolimus
    		≥98.0%
    Zotarolimus (ABT-578) is a derivative of rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis.
    Zotarolimus